GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Siemens Healthineers begins carve-out of diagnostics unit amid China weakness - Finance news and analysis from Global Banking & Finance Review
Finance

Siemens Healthineers begins carve-out of diagnostics unit amid China weakness

Published by Global Banking & Finance Review

Posted on November 5, 2026

2 min read

· Last updated: November 5, 2026

Add as preferred source on Google

Siemens Healthineers Begins Diagnostics Unit Carve-Out, Rebrand to Olyrian Amid China Struggles

By Kira Britten and Paolo Laudani

Siemens Healthineers Diagnostics Unit: Separation, Rebranding, and Market Challenges

Carve-Out and Rebranding Plans

Nov 5 - German medical technology company Siemens Healthineers said on Thursday it had begun carving out its diagnostics business, which it plans to rebrand as Olyrian Diagnostics ahead of a future divestment.

The separation process is expected to be completed by mid-2028.

Diagnostics Unit Overview

The diagnostics unit performs more than 16 billion tests annually and accounts for about 17% of group revenue and 20% of its workforce.

Challenges in the Chinese Market

The business has struggled with weakness in China following healthcare reforms and a transformation programme.

Siemens Healthineers forecast slower-than-expected growth in fiscal 2027 on Thursday as weakness in China continued to weigh on the diagnostics business.

Financial Performance and Transformation Efforts

The unit reported a fourth-quarter adjusted EBIT margin of 5.4% and is targeting an additional 400 million euros ($450 million) of savings as part of its transformation programme.

Turnaround Strategy and Margin Goals

On a call with analysts, Chief Financial Officer Jochen Schmitz said the business would continue its turnaround efforts with the aim of achieving mid-teens margins over the medium term.

Market Reactions and Future Outlook

Deutsche Bank described the quarterly results as "disappointing" but said the decision to separate the diagnostics business was "sensible".

Schmitz said the planned separation would create near-term carve-out and stranded costs but result in a more focused business over the longer term.

Transition Period and Branding

Olyrian Diagnostics will remain part of Siemens Healthineers during the transition period.

The company, which plans to rename itself "Healthineers", said a separate name and brand would help position the unit as a standalone business.

($1 = 0.8880 euros)

(Reporting by Kira Britten and Paolo Laudani in Gdansk; Editing by Matt Scuffham)

Key Takeaways

  • Siemens Healthineers has begun legally separating its diagnostics business, rebranding it as Olyrian Diagnostics, with completion expected by mid‑2028 to prepare for eventual divestment. (siemens-healthineers.com)
  • The diagnostics unit—accounting for over 16 billion annual tests, roughly 17% of group revenue and 20% of its workforce—has been under pressure due to China’s healthcare reforms, dragging on its performance. (wtbx.com)
  • Siemens Healthineers now forecasts fiscal 2027 comparable revenue growth of 4–5%, below expectations, with diagnostics revenue down 4.2% in Q4 and an adjusted EBIT margin of 5.4%. The unit targets €400 million in additional savings and aims for mid‑teens margins over the medium term. (live.euronext.com)

Frequently Asked Questions

Why is Siemens Healthineers carving out its diagnostics unit?
Siemens Healthineers is carving out its diagnostics unit due to ongoing weakness in China, transformation efforts, and to position it as a standalone business ahead of a potential future divestment.
What will Siemens Healthineers' diagnostics unit be renamed?
The diagnostics unit will be rebranded as Olyrian Diagnostics during the carve-out process.
When is the Siemens Healthineers diagnostics separation expected to be completed?
The separation process is expected to be completed by mid-2028.
How significant is the diagnostics unit to Siemens Healthineers' total revenue?
The diagnostics unit accounts for about 17% of group revenue and 20% of the workforce.
What are the financial targets for Olyrian Diagnostics during the transition?
Olyrian Diagnostics aims for an additional 400 million euros in savings and mid-teens EBIT margins over the medium term.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category